Sickle Cell Disease

Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy caused by a single point mutation in the beta-globin gene (HBB, Glu6Val) that produces hemoglobin S (HbS). Under deoxygenated conditions HbS polymerizes, rigidifying and deforming red blood cells into the characteristic sickle shape; sickled cells occlude the microvasculature — causing recurrent, severely painful vaso-occlusive crises and progressive organ damage — and hemolyze prematurely, causing chronic anemia. Disease is most severe in HbSS (sickle cell anemia) and HbS-beta0-thalassemia; HbSC and HbS-beta+-thalassemia are generally milder but still carry real risk of every major complication in this chapter, including stroke and retinopathy — never assume a "milder genotype" patient is safe from an acute complication. A single HbS allele without a second abnormal beta-globin allele — sickle cell trait (HbAS) — is a carrier state, not a disease; it is usually asymptomatic and is covered in Special Populations. Functional asplenia from progressive splenic infarction is present in roughly 94% of children with HbSS by age 5, which makes fever in a person with SCD a genuine medical emergency — never a routine complaint to reassure and monitor at home.^[1][2]

• Inheriting two abnormal beta-globin alleles, at least one of which is HbS: HbSS, HbSC, HbS-beta0-thalassemia, or HbS-beta+-thalassemia. Both biological parents must carry at least one abnormal beta-globin allele.
• Dehydration.
• Hypoxia, including unpressurized high-altitude flight, poorly controlled asthma, and obstructive sleep apnea.
• Cold exposure — peripheral vasoconstriction promotes sickling.
• Infection and fever — a common vaso-occlusive-crisis trigger as well as a direct threat in its own right.
• Physical or emotional stress, and extreme physical exertion.
• Pregnancy — see Special Populations.

Sickle cell genotypes

Diagnosis

Definitive diagnosis requires hemoglobin electrophoresis or high-performance liquid chromatography (HPLC) to identify and quantify the specific hemoglobin variants present — this is what distinguishes HbSS from HbSC from HbS-beta-thalassemia, and it is not interchangeable with a rapid sickle solubility test (e.g., Sickledex), which only detects the presence of HbS, cannot distinguish sickle cell disease from sickle cell trait, and can be falsely negative in a newborn (fetal hemoglobin still dominant) or in a severely anemic patient. Do not use a solubility test alone to rule in or rule out SCD.^[2] Newborn screening for hemoglobinopathies is not yet universal across Canadian provinces and territories, so a first presentation can still be a previously undiagnosed infant or child presenting acutely — maintain suspicion in a child of at-risk ancestry presenting with dactylitis, unexplained anemia, or a vaso-occlusive-type pain crisis.^[1]

Baseline and monitoring investigations

• CBC with differential and reticulocyte count — baseline hemoglobin is typically well below the normal range (commonly 60-90 g/L in HbSS) with an elevated reticulocyte count reflecting ongoing compensatory red cell production; a reticulocyte count that is inappropriately low for the degree of anemia should raise concern for aplastic crisis.
• Peripheral blood smear — sickled cells, target cells, and Howell-Jolly bodies (the latter reflecting functional asplenia).
• Annual transcranial Doppler (TCD) ultrasound in children with HbSS or HbS-beta0-thalassemia, generally from age 2 to 16 years, to screen for stroke risk; an abnormal (high-velocity) result is an indication for chronic transfusion to reduce stroke risk.^[2]

• Prevent and reduce the frequency of vaso-occlusive pain crises and acute chest syndrome.
• Prevent stroke, particularly in children.
• Prevent and promptly treat infection in a functionally asplenic patient.
• Relieve acute pain rapidly and adequately whenever a crisis occurs.
• Manage chronic hemolytic anemia and its complications (gallstones, leg ulcers, pulmonary hypertension, renal disease, retinopathy, avascular necrosis).
• Monitor for and manage iron overload in transfusion-dependent patients.
• Support informed reproductive and genetic-counseling decisions.

• Maintain adequate hydration at all times — oral in the well patient; IV at maintenance rate only (not aggressive/bolus volumes) during an acute crisis or acute chest syndrome, since overhydration itself worsens outcomes in acute chest syndrome.^[3]
• Avoid known triggers where practical: cold exposure, dehydration, hypoxia (including unpressurized high-altitude flight), and extreme physical exertion.
• Use incentive spirometry for any patient admitted with chest or back pain, or with any vaso-occlusive crisis — this measurably reduces the risk of developing acute chest syndrome during that admission.^[3]
• Apply local heat for pain-crisis comfort as an adjunct to, never a substitute for, adequate systemic analgesia.
• Provide genetic counseling for patients and at-risk reproductive partners, and psychosocial support given the real burden of chronic, unpredictable pain.
• Educate every patient/caregiver explicitly: any fever must prompt immediate medical assessment, never a wait-and-see approach.

Disease-modifying and prophylactic therapy

Vaso-occlusive crisis analgesia

Pregnancy

Pregnancy in SCD is genuinely high-risk: more frequent vaso-occlusive crises and acute chest syndrome, and a higher risk of preeclampsia, fetal growth restriction, and preterm birth. Hydroxyurea is contraindicated in pregnancy — discontinue before a planned conception and ensure effective contraception is in place for anyone of reproductive potential taking it; if ongoing disease-modifying therapy is still needed during pregnancy, chronic transfusion is the alternative.^[4] Continue folic acid throughout pregnancy. Manage pregnancy in SCD jointly with a high-risk obstetric team and hematology, not through routine antenatal care alone.

Breastfeeding

Hydroxyurea is contraindicated while breastfeeding, as it is excreted in breast milk.^[4]

Pediatrics

Start hydroxyurea from 9 months of age regardless of severity (from 6 months if symptomatic), start penicillin V prophylaxis at 2 months, and begin annual TCD screening at age 2. Growth rate has not been shown to be adversely affected by hydroxyurea in pediatric trials.^[4]

Perioperative

Any patient with SCD undergoing surgery requiring general anesthesia is at increased risk of vaso-occlusive and acute chest syndrome complications — involve hematology in perioperative planning, avoid prolonged preoperative fasting and dehydration, and maintain oxygenation and warmth throughout the perioperative period.

Sickle cell trait (HbAS) carriers

Sickle cell trait is usually entirely asymptomatic and is not sickle cell disease — it does not require hydroxyurea, antimicrobial prophylaxis, or SCD-level monitoring. It is not, however, entirely risk-free: rare but real associations exist with exertional rhabdomyolysis and exertional sickling under extreme physical exertion (military and intense athletic training), renal medullary carcinoma, and hematuria from renal papillary necrosis. Its main relevance to a pharmacist is genetic counseling for reproductive partners.

Curative and advanced options

Allogeneic hematopoietic stem cell transplant remains the only long-established cure, with the best outcomes from a matched sibling donor in childhood. Exagamglogene autotemcel (Casgevy), a CRISPR/Cas9 gene-edited autologous cell therapy, received Health Canada marketing authorization in September 2024 for patients 12 years of age and older with recurrent vaso-occlusive crises — a genuine, currently available (though highly specialized, limited-center) option, unlike voxelotor, crizanlizumab, or L-glutamine. Refer a patient with recurrent severe crises despite optimized hydroxyurea to a specialized SCD/transplant centre for eligibility evaluation rather than assuming no further options exist.

• Regular hematology follow-up for all patients; more frequent during hydroxyurea titration (see Drug Tables for the exact schedule).
• Annual TCD ultrasound, ages 2-16, in HbSS/HbS-beta0-thalassemia.^[2]
• Annual dilated ophthalmologic exam from around age 10 to screen for sickle retinopathy — proportionally more important in HbSC.
• Annual urinalysis/albuminuria screening and renal function testing for sickle nephropathy.
• Periodic echocardiogram and pulmonary function assessment in adults to screen for pulmonary hypertension.
• In transfusion-dependent patients: serial ferritin plus periodic cardiac and liver T2* MRI — MRI is the more reliable measure of true iron burden than ferritin alone — to guide chelation therapy.^[6]
• Review vaccination status and hydroxyurea adherence at every visit.

1. For an inadequate hydroxyurea response: confirm adherence first, confirm the patient is genuinely at the maximum tolerated dose (not a dose left unescalated by default), and allow a full 6-month trial at that dose before concluding the drug has failed.^[4]
2. For recurrent severe crises despite an optimized, adherent hydroxyurea regimen: consider chronic transfusion therapy, and refer to a specialized sickle cell/transplant centre to evaluate eligibility for allogeneic hematopoietic stem cell transplant or CRISPR-based gene therapy (exagamglogene autotemcel/Casgevy, Health Canada-approved since September 2024 for age 12 and older with recurrent vaso-occlusive crises) — these are genuine current options, not merely research.
3. For a vaso-occlusive crisis not adequately controlled by the patient's usual home regimen: refer to the emergency department for parenteral opioid titration rather than repeating or escalating an oral regimen indefinitely at home.
4. For pain that remains poorly controlled despite reasonable parenteral opioid titration in hospital: reassess for acute chest syndrome, splenic sequestration, or another evolving complication before assuming simple analgesic failure, and involve acute pain/hematology specialists.^[5]

• Treating fever in a person with SCD as a routine, reassurance-and-monitor complaint — functional asplenia makes this a genuine sepsis risk requiring immediate assessment.
• Under-treating vaso-occlusive pain out of concern about opioid misuse — genuine, often high, opioid requirements are a real and expected feature of severe crisis pain, not evidence of drug-seeking behaviour; undertreated pain is real, documented harm.^[5]
• Giving iron empirically for the anemia of SCD — patients with SCD are not iron deficient at baseline, and inappropriate iron supplementation on top of chronic hemolysis (and, in transfusion-dependent patients, transfusional iron loading) risks worsening iron overload.
• Missing acute chest syndrome in a patient admitted for an uncomplicated-seeming pain crisis — use routine incentive spirometry and oxygen saturation monitoring for every SCD admission, not only once respiratory symptoms are already present.^[3]
• Giving aggressive or bolus IV fluids in suspected or confirmed acute chest syndrome — maintenance-rate fluids only; overhydration worsens pulmonary status.^[3]
• Using meperidine for vaso-occlusive crisis pain — accumulation of its neurotoxic metabolite normeperidine causes seizures, a particular concern in a population that may receive repeated dosing across multiple admissions.
• Assuming sickle cell trait (HbAS) is a form of the disease requiring hydroxyurea, prophylaxis, or crisis-level monitoring — it is a carrier state, not SCD.
• Assuming voxelotor, crizanlizumab, or L-glutamine are current, accessible Canadian treatment options to discuss with a patient — none has a Health Canada-approved product, and voxelotor has been withdrawn from every world market.^[7]

How to use this table: Doses are adult doses unless stated otherwise and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Disease-modifying therapy

Titrate to the maximum tolerated dose for each patient, based on laboratory monitoring and clinical response — the goal is not a fixed target dose but the highest dose the patient's blood counts can safely sustain.

Adjunct supplementation

Antimicrobial prophylaxis (children with HbSS/HbS-beta0-thalassemia)

Tablets are preferable to suspension for shelf-life reasons and may be crushed for younger children. Start at 2 months of age and continue to at least age 5; continue indefinitely after invasive pneumococcal disease, surgical splenectomy, incomplete immunization status, or a history of inconsistent adherence.

Immunizations: children with SCD require the full routine childhood schedule plus an enhanced schedule against the encapsulated organisms functional asplenia leaves them vulnerable to — pneumococcal conjugate and polysaccharide vaccines, meningococcal conjugate (ACYW) and serogroup B vaccines, and a booster dose of Hib conjugate vaccine from age 5 — together with annual influenza and, where not already given in infancy, hepatitis B vaccination. Follow the current Canadian Immunization Guide/NACI schedule for exact products, dosing intervals, and booster timing, since vaccine formulations and recommended intervals continue to evolve.^[1]

Vaso-occlusive crisis analgesia

Give parenteral opioids with monitoring for oversedation. Titrate to the level of pain reported, not to a fixed dose regardless of response — respiratory depression is rare when dosing is genuinely response-guided.

Iron chelation (transfusion-dependent patients)

Reserve for patients with confirmed transfusional iron overload, guided by serial ferritin and periodic cardiac/liver T2* MRI rather than ferritin alone.

Evidence note: Drug inventory, dosing, monitoring, and comments reflect current Canadian practice, cross-checked against the CanHaem Consensus Statement on the Care of Patients with Sickle Cell Disease in Canada, the 2014 NHLBI expert panel report, and the 2020 ASH sickle cell disease guidelines on pain and transfusion support.